10-K: Alkermes Reports Mixed 2025 Results Amid Strategic Shifts

Alkermes plc reported a decrease in net income for 2025 despite strong proprietary product sales, driven by expiring royalties and increased R&D investments, while completing a major acquisition and advancing its neuroscience pipeline.

Summary

• Net income from continuing operations decreased to $241.7 million in 2025 from $372.1 million in 2024, primarily due to increased expenses and a significant drop in manufacturing and royalty revenues.
• Total revenues for 2025 were $1,475.9 million, down from $1,557.6 million in 2024.
• Proprietary product sales, net, increased by $101.1 million to $1,184.6 million in 2025, driven by LYBALVI sales growth and price increases across key products.
• LYBALVI sales increased by $66.7 million, with a 19% increase in units sold, while ARISTADA and ARISTADA INITIO sales rose by $23.8 million, and VIVITROL sales increased by $10.6 million.
• Manufacturing and royalty revenues decreased by $182.8 million to $291.3 million in 2025, largely due to the expiration of U.S. royalties on INVEGA SUSTENNA in August 2024 and reduced manufacturing for other legacy products.
• Research and development expenses increased by $78.7 million to $324.0 million in 2025, primarily due to the advancement of the Alixorexton development program and preclinical activities.
• Selling, general and administrative expenses increased by $56.3 million to $701.5 million, driven by higher employee-related costs and professional service fees for the Avadel Acquisition.
• The Avadel Pharmaceuticals plc acquisition was successfully completed on February 12, 2026, adding LUMRYZ to the commercial portfolio and a narcolepsy-focused commercial organization.
• Alixorexton (formerly ALKS 2680) received FDA Breakthrough Therapy designation for Narcolepsy Type 1 (NT1) in December 2025, following positive Phase 2 study results.
• Patient enrollment for the Phase 3 REVITALYZ study of LUMRYZ in idiopathic hypersomnia (IH) was completed in December 2025.
• The company prepaid $289.5 million of long-term debt in December 2024 and incurred approximately $1.525 billion in new debt (TLA and TLB Facilities) in February 2026 to fund the Avadel Acquisition.
• No share repurchases were made in 2025 under the $400.0 million program, which had $200.0 million remaining authorization as of December 31, 2025.
• The sale of the Athlone Facility to Novo Nordisk was completed in May 2024, with subcontracting arrangements concluding by the end of 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed filing. While proprietary product sales show strong growth and the Avadel acquisition adds a promising new product, the significant decline in net income and overall revenue due to expiring royalties and increased R&D spend presents a challenge. The new debt for the acquisition also adds financial leverage, though it's for a strategic growth initiative.

Positives

• Proprietary product sales, net, increased by $101.1 million in 2025, demonstrating strong performance for ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.
• LYBALVI sales grew significantly by $66.7 million, with a 19% increase in units sold, indicating strong market acceptance.
• The successful completion of the Avadel Pharmaceuticals plc acquisition on February 12, 2026, adds LUMRYZ, a first-in-class once-at-bedtime narcolepsy treatment, and a specialized commercial team.
• Alixorexton received FDA Breakthrough Therapy designation for Narcolepsy Type 1 (NT1) in December 2025, highlighting its potential and expediting its development pathway.
• Positive topline data from two Phase 2 studies (Vibrance-1 and Vibrance-2) for Alixorexton in NT1 and NT2 were announced in 2025.
• Patient enrollment for the Phase 3 REVITALYZ study of LUMRYZ in idiopathic hypersomnia (IH) was completed in December 2025, indicating progress towards potential new indications.
• The company prepaid $289.5 million of previously outstanding long-term debt in December 2024, reducing prior financial obligations.
• Medicaid rebates as a percentage of sales decreased in 2025 due to gross-to-net favorability, with actual rebates lower than original estimates for VIVITROL and ARISTADA/ARISTADA INITIO by $26.7 million and $13.6 million, respectively.
• The 2025 global voluntary attrition rate of 7.0% was below industry benchmarks, indicating strong employee retention.

Negatives

• Net income from continuing operations decreased by $130.5 million in 2025 compared to 2024, primarily due to higher expenses and lower manufacturing and royalty revenues.
• Total revenues decreased by $81.7 million in 2025, largely driven by a significant decline in manufacturing and royalty revenues.
• Manufacturing and royalty revenues decreased by $182.8 million, primarily due to the expiration of U.S. royalties on INVEGA SUSTENNA in August 2024, which comprised a significant portion of previous royalty streams.
• Revenues from RISPERDAL CONSTA decreased by $3.9 million, and are expected to continue decreasing due to patent expirations and generic competition.
• Other manufacturing and royalty revenue decreased by $48.5 million, mainly due to the conclusion of FAMPYRA manufacturing obligations and reduced revenue from legacy products.
• Research and development expenses increased by $78.7 million, reflecting significant investment in pipeline programs, which impacts current profitability.
• Selling, general and administrative expenses increased by $56.3 million, partly due to increased headcount and professional service fees related to the Avadel Acquisition.
• The company incurred approximately $10.0 million in costs related to the Avadel Acquisition during Q4 2025.
• The company did not repurchase any ordinary shares under its Repurchase Program in 2025, despite $200.0 million remaining authorized.

Risks

• Substantial revenue from key proprietary products, and success depends on the ability to successfully manufacture and commercialize them.
• Intense competition in the biopharmaceutical industry from research institutions, other biopharmaceutical companies (including those with similar technologies or medicines), and generic drug manufacturers.
• Revenues from product sales may decrease or grow at a slower than expected rate due to factors like physician perception, unfavorable publicity, cost-effectiveness, regulatory exclusivities, REMS compliance, raw material availability, manufacturing success, market size, competitive landscape, adverse event information, product label changes, unfavorable litigation outcomes, and regulatory actions.
• Dependence on third-party payers for reimbursement, and potential reductions in payment rates or increases in patient cost-sharing could decrease sales and revenues.
• Failure to realize anticipated benefits and synergies of the Avadel Acquisition or to successfully integrate Avadel's business could adversely affect business and financial condition.
• Changes in, or failure to comply with, extensive legal and regulatory requirements affecting the healthcare industry could lead to investigations, litigation, costs, penalties, and business losses.
• Reliance on licensees for commercialization and continued development of products from which revenue is received; ineffectiveness of licensees or disputes could materially adversely affect revenues.
• Clinical trials for product candidates are expensive, lengthy, and outcomes are uncertain, with a high risk of not successfully completing development or receiving marketing approval.
• Preliminary, topline, or interim data from clinical trials may change as more patient data become available or based on subsequent audit and verification procedures, and may not be indicative of final data or real-world results.
• Success depends on obtaining and maintaining regulatory approval for products, which can be delayed, limited, or not granted due to various factors, including differing interpretations of data by regulatory agencies.
• Disruptions at the FDA, SEC, and other government agencies (e.g., government shutdowns, leadership changes) could negatively impact the business.
• Inability to successfully expand the R&D pipeline or commercial product portfolio could limit growth potential, as transactional opportunities are competitive and may not yield anticipated returns.
• Risks related to the manufacture of products, including unanticipated interruptions, delays, product defects, shortages, or failures to comply with cGMP regulations, especially given reliance on a single manufacturing facility for several key products.
• Reliance on third parties for goods and services in manufacturing and distribution, with potential for disruptions due to external events or quality/operational issues.
• LUMRYZ is a controlled substance subject to U.S. federal and state laws and regulations, and non-compliance or high compliance costs could materially adversely affect the business.
• Success depends on the ability to attract, recognize, and retain key personnel, with intense competition for skilled employees.
• Patent and other intellectual property (IP) protection for products is key but uncertain, with risks of challenges, invalidation, or circumvention by competitors.
• Uncertainty over IP in the biopharmaceutical industry is a source of litigation and other legal proceedings, including claims of infringement and competition from generic drug manufacturers.
• Litigation or arbitration filed against Alkermes, including securities litigation, or citizen petitions against regulatory agencies, may result in financial losses, harm reputation, or negatively impact product approval.
• Inability to maintain profitability on a sustained basis, dependent on revenue growth, diversification, and cost management.
• Adverse tax consequences for U.S. holders if non-U.S. subsidiaries are characterized as controlled foreign corporations (CFCs).
• Significant charges against earnings if goodwill becomes impaired.
• Effective tax rate may increase due to profit distribution, tax law interpretations, or changes in tax laws.
• Deferred tax assets may not be realized, especially if future taxable income is insufficient.
• Disposition of the Athlone Facility may limit the ability to use net operating losses (NOLs) and result in unanticipated tax liabilities.
• IRS may not agree with the conclusion that Alkermes plc should be treated as a foreign corporation for U.S. federal income tax purposes.
• Significant tax liabilities for Alkermes and/or shareholders if the separation of the oncology business does not ultimately qualify as generally tax-free for U.S. federal and Irish tax purposes.
• Debt obligations could adversely affect the business and limit the ability to plan for or respond to changes.
• Future transactions may harm the market price of ordinary shares or require additional funds, which may not be available on favorable terms or cause dilution.
• Currency exchange rates may affect revenues and expenses, particularly with international business operations.
• Volatility in the market price of ordinary shares due to market, industry, and company-specific factors.
• Negative impact from actions of activist shareholders, including costly proxy contests and diversion of management attention.
• Information security breaches and other disruptions could compromise information and expose the company to liability.
• Subject to numerous and varying privacy and security laws (e.g., GDPR, HIPAA), with non-compliance potentially leading to penalties and reputational damage.
• Changes in global trade or other policies, including tariffs, could have an adverse effect on business.
• A future pandemic, epidemic, or outbreak of an infectious disease may materially and adversely affect the business.
• Material weakness in internal control over financial reporting could negatively affect reporting obligations and share price.
• Increasing use of social media platforms and artificial intelligence tools present new risks and challenges, including regulatory violations and reputational harm.

Future Outlook

The company expects R&D expenses to increase in 2026 due to the planned initiation of the Phase 3 program for Alixorexton and the advancement of early-stage development candidates ALKS 4510 and ALKS 7290. Revenues from RISPERDAL CONSTA are expected to continue decreasing due to patent expirations and increased competition. The company anticipates its existing cash, cash equivalents, restricted cash, and investments will be sufficient to finance anticipated working capital, debt services, and capital expenditures for at least the next twelve months. The company will continue to monitor the need for a valuation allowance against its deferred tax assets quarterly.

Management Comments

• Management believes that ARISTADA, ARISTADA INITIO, LYBALVI, VIVITROL, VUMERITY, and the newly acquired LUMRYZ are singular or competitively advantaged products expected to generate significant revenues in the nearand medium-term.
• The company intends to vigorously defend its intellectual property in ongoing patent infringement lawsuits related to LYBALVI and the antitrust class action litigation concerning VIVITROL.
• Management is committed to supporting employee well-being in a transparent, inclusive, and collaborative environment, providing training, support, and resources for professional success.
• The company is committed to designing and managing pay programs and decisions to support equitable pay for all employees, based on market and benchmark data, and routinely monitors pay programs to respond to market trends and maintain equity.

Industry Context

StockSavvy.ai notes that Alkermes' 2025 performance reflects a common challenge in the biopharmaceutical industry: balancing the growth of proprietary products with the decline of revenues from older, licensed products facing patent expirations and generic competition. The strategic acquisition of Avadel and LUMRYZ positions Alkermes strongly in the narcolepsy market, a growing neuroscience segment. The significant investment in R&D for Alixorexton, coupled with its Breakthrough Therapy designation, indicates a focus on high-potential, innovative therapies, aligning with industry trends towards addressing unmet medical needs in neuroscience. However, the industry continues to grapple with increasing regulatory scrutiny on drug pricing (e.g., Inflation Reduction Act, MFN initiatives) and ongoing patent litigation, which can create significant financial and operational uncertainties for companies like Alkermes.

Comparison to Industry Standards

• In the schizophrenia treatment market, ARISTADA, LYBALVI, and RISPERDAL CONSTA compete with products like ZYPREXA RELPREVV (Lilly), ABILIFY MAINTENA and ABILIFY ASIMTUFII (Otsuka Pharm. Co.), RYKINDO (Luye Pharma Group), UZEDY (MedinCell S.A. and Teva), and generic risperidone formulations. LYBALVI also competes with oral antipsychotics such as CAPLYTA (Johnson & Johnson), REXULTI (Otsuka Pharm Co. and H. Lundbeck A/S plc), VRAYLAR (Abbvie Inc.), and COBENFY (Bristol-Myers Squibb Company).
• For alcohol and opioid dependence, VIVITROL competes with generic acamprosate calcium (CAMPRAL), generic disulfiram (ANTABUSE), other naltrexone formulations, SUBOXONE, SUBUTEX, SUBLOCADE (Indivior plc), BUNAVAIL (BioDelivery Sciences), ZUBSOLV (Orexo US, Inc.), BRIXADI (Braeburn Inc.), and methadone.
• In multiple sclerosis, VUMERITY competes with a wide array of established treatments including AVONEX, TYSABRI, TECFIDERA, PLEGRIDY (Biogen), OCREVUS (Genentech), BETASERON (Bayer HealthCare Pharmaceuticals), COPAXONE (Teva), REBIF, MAVENCLAD (EMD Serono, Inc.), GILENYA, EXTAVIA, MAYZENT (Novartis AG), AUBAGIO, LEMTRADA (Sanofi-Aventis), ZEPOSIA (Bristol-Myers Squibb Company), PONVORY (Janssen), and BRIUMVI (TG Therapeutics, Inc.).
• For narcolepsy, LUMRYZ competes with twice-nightly oxybate formulations like XYWAV and XYREM (Jazz Pharmaceuticals plc), as well as daytime wake-promoting agents such as VYVANSE, dextroamphetamine, methylphenidate, amphetamine, modafinil, armodafinil, SUNOSI (Axsome Therapeutics, Inc.), WAKIX (Harmony Biosciences Holdings, Inc.), and generic versions of XYREM. Alkermes' Alixorexton is also in development as a potential competitor in this space.

Corporate Governance

Legal Proceedings

• Janssen Pharmaceutica, Janssen Pharmaceuticals, Inc., and Janssen Research & Development, LLC prevailed in a patent infringement lawsuit against Mylan Laboratories Limited regarding INVEGA TRINZA, with the U.S. Court of Appeals for the Federal Circuit affirming the decision in March 2025 and denying rehearing in July 2025. Alkermes was not a party to this specific proceeding.
• Alkermes Pharma Ireland Limited (APIL) and Alkermes, Inc. filed patent infringement lawsuits against Teva, Apotex, and MSN in August and September 2025, respectively, following Paragraph IV certifications for generic LYBALVI. These lawsuits triggered 30-month stays of FDA approval for the generic ANDAs.
• Value Drug Company filed an antitrust class action complaint against Alkermes, Inc. and APIL in October 2025, alleging fraudulent obtainment and enforcement of a VIVITROL patent, seeking unspecified money damages. Alkermes filed a motion to dismiss in December 2025.
• The company is cooperating with a civil investigative demand from a U.S. state governmental authority.
• Acorda Therapeutics, Inc.'s appeal of a U.S. District Court decision (which confirmed an arbitral award but declined to increase damages) was transferred to the U.S. Court of Appeals for the Second Circuit in July 2025.

Stakeholder Impact

• Shareholders: Experienced a decrease in net income and EPS in 2025, but proprietary product sales growth and strategic acquisition of LUMRYZ could drive future value. The new debt for the acquisition increases financial leverage. Share repurchase program remains active with $200.0 million authorized.
• Employees: The company maintains a focus on employee well-being, competitive compensation, and professional development, with a low voluntary attrition rate. The Avadel acquisition integrated a new commercial organization.
• Customers/Patients: New products like LUMRYZ and Alixorexton aim to address unmet medical needs in neuroscience. However, generic competition for VIVITROL and potential pricing pressures from government initiatives could impact access or cost.
• Licensees/Partners: Royalty revenues from Janssen's long-acting INVEGA products decreased due to patent expirations, impacting revenue from these collaborations. The manufacturing transition for VUMERITY to Biogen concluded.

Next Steps

• Initiate a Phase 3 program for Alixorexton in narcolepsy in the first quarter of 2026.
• Continue to integrate Avadel's business into Alkermes, including operational and administrative systems.
• Monitor and manage compliance with the LUMRYZ REMS and other regulatory requirements for controlled substances.
• Vigorously defend intellectual property in ongoing patent infringement lawsuits related to LYBALVI and the antitrust class action litigation concerning VIVITROL.
• Evaluate manufacturing capacity based on demand for products and periodically assess long-lived assets for impairment.
• Monitor the impact of the Inflation Reduction Act and other healthcare reforms on product pricing and reimbursement.
• Continue to assess and mitigate potential impacts of global trade policies and public health developments.
• Conduct periodic employee engagement surveys to inform and evolve human capital management strategy.

Key Dates

Recommendation

Alkermes presents a mixed financial picture for 2025, with strong growth in proprietary product sales offset by a significant decline in manufacturing and royalty revenues due to patent expirations. The strategic acquisition of Avadel and its narcolepsy drug LUMRYZ, coupled with the Breakthrough Therapy designation for Alixorexton, indicates a clear path for future growth and pipeline strength in neuroscience. However, the substantial debt incurred for the acquisition, ongoing legal challenges, and the uncertain impact of evolving healthcare pricing regulations (like the Inflation Reduction Act and MFN initiatives) introduce considerable risk. While the long-term outlook for the proprietary pipeline is promising, the immediate financial performance and regulatory headwinds suggest a 'hold' recommendation until there is clearer visibility on the integration of Avadel, the financial impact of new debt, and the resolution of key legal and regulatory uncertainties.

Keywords

Neuroscience, Biopharmaceutical, Schizophrenia, Bipolar I Disorder, Narcolepsy, Opioid Dependence, Alcohol Dependence, ARISTADA, LYBALVI, VIVITROL, LUMRYZ, Alixorexton, Drug Development, Clinical Trials, FDA, SEC, Intellectual Property, Patent Litigation, Acquisition, Avadel Pharmaceuticals, Share Repurchase, Financial Performance, Revenue, Net Income, R&D, Manufacturing, Regulatory Compliance, Healthcare Policy, Ireland, United States